HOWL

The past six months have seen several events impacting Werewolf Therapeutics, Inc.'s stock price. The company reported Q1 2026 financial results, with a net loss of $13.5M and cash at $46.5M. The MACD for HOWL turned negative, and the Momentum Indicator moved below 0. Werewolf Therapeutics reported Q4 and full-year 2025 financial results and announced the initiation of a strategic review. The company publicly announced its plan to explore strategic alternatives to maximize stockholder value. The Board of Directors approved a 64% workforce reduction to lower operating costs. Werewolf Therapeutics received a notice of non-compliance from Nasdaq regarding its bid price deficiency and audit committee membership requirements. Multiple 10% owners collectively sold 242,890 shares of common stock. The company reported Q3 2025 financial results, emphasizing cash of $65.7M and pipeline milestones. Werewolf Therapeutics received Fast Track Designation from the U.S. Food and Drug Administration for its WTX-124 therapy. Werewolf Therapeutics presented data expanding its PREDATOR platform at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting.